ALTO NEUROSCIENCE, INC.

MOUNTAIN VIEW, CA · Founded 2019 · Medtech · Still private

EEG-based machine learning biomarkers for psychiatric disorder stratification and treatment prediction

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · altoneuroscience.com

Sector: Medtech
Headquarters: MOUNTAIN VIEW, CA
Founded: 2019
Latest Form D: $50M, Oct 2025
Total capital: $197M

Federal grants: $3.2M; 3 awards · 2020–2022; Rank in peer group#30 of 53
Private capital raised: $194M; 5 Form D · last Oct 2025; 12 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 7; 33 pending · first 2025; Rank in peer group#6 of 53

Capital timeline

Latest events

Oct 2025Private capital raisedForm D · SEC · 5th filing$50M
Nov 2023Private capital raisedForm D · SEC · 4th filing$7.7M
Nov 2023Private capital raisedForm D · SEC · 3rd filing$31.9M
Nov 2023Private capital raisedForm D · SEC · 2nd filing$59.3M
Nov 2023Private capital raisedForm D · SEC · 1st filing$45M
Jan 2022Federal grantHealth and Human S · Phase II · Validating of Machine Learning-Based EEG Treatment Biomarkers in Depression$1M
Mar 2021Federal grantHealth and Human S · Phase II · Validating of Machine Learning-Based EEG Treatment Biomarkers in Depression$1.2M

Show 1 earlier federal award

Feb 2020Federal grantHealth and Human S · Phase II · Validating of Machine Learning-Based EEG Treatment Biomarkers in Depression$988K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

45months

from ALTO NEUROSCIENCE, INC.’s first federal award to its first private round.

First federal award · Feb 2020: Health and Human S · $988K
First Form D · Nov 2023: $45M · 1st Form D
Awards before first raise: 3 awards

An association in public records, not a cause or a prediction.

Standing among 53 peers

Line = median

Medtech · Software

Federal grantsBelow median
Granted patents#6 · top 11%
Linked publications#2 · top 4%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Amit EtkinResearcherExecutive Officer, DirectorLinked by 1 patent · $3.2M in grants as PI
Aaron WeaverDirectorNamed in SEC Form D filings
Adam SavitzExecutive OfficerNamed in SEC Form D filings
Andrew Nixon DreyfusDirectorNamed in SEC Form D filings
Chris Nixon DimitropoulosDirectorNamed in SEC Form D filings
Christopher Nixon CoxDirectorNamed in SEC Form D filings

Show all 13 people

Gwill YorkDirectorNamed in SEC Form D filings
Husseini Nixon ManjiDirectorNamed in SEC Form D filings
Michael HanleyExecutive OfficerNamed in SEC Form D filings
Michael Nixon LiangDirectorNamed in SEC Form D filings
Nicholas SmithExecutive OfficerNamed in SEC Form D filings
Po Yu (Jeff) ChenDirectorNamed in SEC Form D filings
Raymond Nixon SanchezDirectorNamed in SEC Form D filings

What it has protected

USPTO · 7 granted of 40

Sep 3, 2026PendingCombination Therapy For A Dopamine AgonistUSPTOApplication 19653745
Aug 13, 2026PendingPlacebo Response Prediction For Psychiatric PatientsUSPTOApplication 19537878
Aug 6, 2026PendingEeg Montage For Facilitating Selection Of Drug Treatment In Patients Suffering From Psychiatric DisordersUSPTOApplication 19532015

Show all 40 patent records

Combination Therapy For A Dopamine AgonistSep 3, 2026 · Application 19653745Pending
Placebo Response Prediction For Psychiatric PatientsAug 13, 2026 · Application 19537878Pending
Eeg Montage For Facilitating Selection Of Drug Treatment In Patients Suffering From Psychiatric DisordersAug 6, 2026 · Application 19532015Pending
Combination Therapy For A Dopamine AgonistJun 9, 2026 · US 12,648,934Granted
Combination Therapy For A Dopamine AgonistMay 28, 2026 · Application 19453621Pending
Integration Of Molecular Mechanisms In The Striatum As A Combination Drug Strategy For The Treatment Of Psychiatric And Neurological Disorders In Which Anhedonia Or Motivation-related Dysfunction ExistsMay 21, 2026 · Application 19450399Pending
Anti-neurodegenerative Combinations And Use For Treatment Of Neurodegenerative DiseasesMay 12, 2026 · US 12,622,895Granted
Eeg Montage For Facilitating Selection Of Drug Treatment In Patients Suffering From Psychiatric DisordersApr 7, 2026 · US 12,594,028Granted
Method For Improving NeuroplasticityMar 5, 2026 · Application 19316824Pending
Combination Therapy For A Dopamine AgonistJan 13, 2026 · US 12,521,374Granted
Effective Treatment Of Depression In Patients Having Impaired Learning And/or Memory Or Certain Eeg Characteristics With A Benzylpiperazine-aminopyridine AgentJun 5, 2025 · Application 19052783Pending
Method Of Treatment Of Depressed Patients With Poor Cognition And Selection Of Other Patients Benefiting From A Benzylpiperazine-aminopyridine AgentJun 5, 2025 · Application 19040204Pending
Method Of Treatment And Selection Of Patients Benefiting From Agomelatine Based On Eeg MeasurementsJun 5, 2025 · Application 19043072Pending
Treatment Of Psychiatric Or Neurological Disorders In Patients With Prominent Anhedonia Using Irdabisant As A Monotherapy Or In Combination With An Antipsychotic AgentMay 8, 2025 · Application 18933579Pending
Treatment Of Neuropsychiatric Disorders With TilivapramApr 17, 2025 · Application 18896294Pending
Effective Treatment Of Depression In Patients Having Impaired Learning And/or Memory Or Certain Eeg Characteristics With A Benzylpiperazine-aminopyridine AgentFeb 25, 2025 · US 12,233,059Granted
Method Of Treatment And Selection Of Patients Benefiting From Agomelatine Based On Eeg MeasurementsFeb 18, 2025 · US 12,226,375Granted
Method Of Treatment And Selection Of Patients Benefiting From Agomelatine Based On Eeg MeasurementsFeb 13, 2025 · Application 18670524Pending
Method Of Treatment And Selection Of Patients Benefiting From Agomelatine Based On Eeg MeasurementsFeb 13, 2025 · Application 18670556Pending
Effective Treatment Of Depression In Patients Having Impaired Learning And/or Memory Or Certain Eeg Characteristics With A Benzylpiperazine-aminopyridine AgentJan 28, 2025 · US 12,208,096Granted
Effective Treatment Of Depression In Patients Having Impaired Learning And/or Memory Or Certain Eeg Characteristics With A Benzylpiperazine-aminopyridine AgentJan 9, 2025 · Application 18892030Pending
Method Of Treatment Of Depressed Patients With Poor Cognition And Selection Of Other Patients Benefiting From A Benzylpiperazine-aminopyridine AgentOct 17, 2024 · Application 18670580Pending
Method Of Treatment Of Depressed Patients With Poor Cognition And Selection Of Other Patients Benefiting From A Benzylpiperazine-aminopyridine AgentOct 17, 2024 · Application 18670604Pending
Effective Treatment Of Depression In Patients Having Impaired Learning And/or Memory Or Certain Eeg Characteristics With A Benzylpiperazine-aminopyridine AgentSep 26, 2024 · Application 18670632Pending
Method Of Treatment Of Depressed Patients With Poor Cognition And Selection Of Other Patients Benefiting From A Benzylpiperazine-aminopyridine AgentSep 19, 2024 · Application 18670588Pending
Method Of Treatment Of Depressed Patients With Poor Cognition And Selection Of Other Patients Benefiting From A Benzylpiperazine-aminopyridine AgentSep 19, 2024 · Application 18670599Pending
Effective Treatment Of Depression In Patients Having Impaired Learning And/or Memory Or Certain Eeg Characteristics With A Benzylpiperazine-aminopyridine AgentSep 19, 2024 · Application 18670619Pending
Effective Treatment Of Depression In Patients Having Impaired Learning And/or Memory Or Certain Eeg Characteristics With A Benzylpiperazine-aminopyridine AgentJun 20, 2024 · Application 18528486Pending
Enhancement Of Camp Signaling As A Combination Drug Strategy For The Treatment Of Psychiatric And Neurological Disorders In Which Depressive, Anhedonia, Motivation-related Or Cognition-related Dysfunction ExistsApr 20, 2023 · Application 18063907Pending
Method Of Treatment Of Depressed Patients With Poor Cognition And Selection Of Other Patients Benefiting From A Benzylpiperazine-aminopyridine AgentDec 8, 2022 · Application 17805374Pending
Integration Of Molecular Mechanisms In The Striatum As A Combination Drug Strategy For The Treatment Of Psychiatric And Neurological Disorders In Which Anhedonia Or Motivation-related Dysfunction ExistsJul 21, 2022 · Application 17648538Pending
Composition And Use For The Treatment Of Parkinson's Disease And Related DisordersNov 4, 2021 · Application 17279644Pending
Compositions And Method For Treating DepressionDec 3, 2020 · Application 16607252Pending
Method Of Treatment Of Depressed Patients With Poor Cognition And Selection Of Other Patients Benefiting From A Benzylpiperazine-aminopyridine AgentApplication PCTUS2022032136Pending
Enhancement Of Camp Signaling As A Combination Drug Strategy For The Treatment Of Depression And Related ConditionsApplication PCTUS2022013197Pending
Integration Of Molecular Mechanisms In The Striatum As A Combination Drug Strategy For The Treatment Of Psychiatric And Neurological Disorders In Which Anhedonia Or Motivation-related Dysfunction ExistsApplication PCTUS2022013194Pending
Method Of Treatment Of Depressed Patients With Poor Cognition And Selection Of Other Patients Benefiting From A Benzylpiperazine-aminopyridine AgentApplication 63264269Pending
Method Of Treatment Of Depressed Patients With Poor Cognition And Selection Of Other Patients Benefiting From A Benzylpiperazine-aminopyridine AgentApplication 63263168Pending
Method Of Treatment Of Depressed Patients With Poor Cognition And Selection Of Other Patients Benefiting From A Benzylpiperazine-aminopyridine AgentApplication 63202254Pending
Integration Of Molecular Mechanisms In The Striatum As A Combination Drug Strategy For The Treatment Of Depression And Related ConditionsApplication 63199723Pending

Recent research by its founders

Brain Neuroplasticity Mechanisms in Psychiatric Illnesses and in the Development of Novel Treatments20263 cites
Childhood Maltreatment and Deviations From Normative Brain Structure: A Mega-Analysis of 3711 Individuals From the ENIGMA Major Depressive Disorder and ENIGMA Posttraumatic Stress Disorder Working Groups20261 cites
Multimodal evidence for hippocampal engagement and modulation by functional connectivity-guided parietal TMS20260 cites

ELEMENTS ENDOSCOPY INCSimilar federal contract value in Medtech · null in contracts
SILBIOTECH, INC.Similar federal contract value in Medtech · null in contracts
PERCEPTIVE TECHNOLOGIES, INC.Similar federal contract value in Medtech · null in contracts
ESK THERAPEUTICS, INCSimilar federal contract value in Medtech · null in contracts
KURIA THERAPEUTICS, INCSimilar federal contract value in Medtech · null in contracts
REKOVAR INC.Similar federal contract value in Medtech · null in contracts

Regulatory activity · Medtech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.